MedPath

Nevirapine

Generic Name
Nevirapine
Brand Names
Viramune
Drug Type
Small Molecule
Chemical Formula
C15H14N4O
CAS Number
129618-40-2
Unique Ingredient Identifier
99DK7FVK1H
Background

A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.

Indication

For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
-
Clinical Trials
Related News

Study to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) in HIV+ Patients

Phase 4
Completed
Conditions
HIV Infections
Interventions
Drug: Nevirapine
Drug: Rifabutin
First Posted Date
2014-07-09
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
19
Registration Number
NCT02184078

Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected Patients

Phase 4
Completed
Conditions
HIV Infections
Interventions
Drug: Nevirapine
Drug: Prednisone
First Posted Date
2014-07-09
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
138
Registration Number
NCT02184299

Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults

Phase 1
Terminated
Conditions
HIV Infections
Interventions
Drug: Abacavir
Drug: Nevirapine
Drug: Amprenavir
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
8
Registration Number
NCT02182765

Effects of Nevirapine on the Steady State Pharmacokinetics of Fluconazole in HIV Positive Patients

Phase 4
Completed
Conditions
HIV Infections
Interventions
Drug: Fluconazole
Drug: Nevirapine
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT02181946

Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women

Phase 3
Completed
Conditions
HIV Infections
Interventions
Drug: Zidovudine (ZDV)
Drug: Nevirapine
Drug: Lamivudine (3TC)
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
2648
Registration Number
NCT02181933

Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE) and Ethinyl Estradiol/Norethindrone in HIV-1 Infected Women

Phase 1
Completed
Conditions
HIV Infections
Interventions
Drug: EE/NET
Drug: Nevirapine
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
14
Registration Number
NCT02182791

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

Phase 1
Recruiting
Conditions
HIV Infection
Interventions
Drug: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Drug: Nevirapine (NVP)
Drug: Raltegravir (RAL)
Drug: Lopinavir/Ritonavir (LPV/r)
Drug: VRC01
Drug: DTG
Drug: VRC07-523LS
First Posted Date
2014-05-16
Last Posted Date
2024-08-09
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
1120
Registration Number
NCT02140255
Locations
🇺🇸

5040, SUNY Stony Brook Clinical Research Site, Stony Brook, New York, United States

🇺🇸

5112, David Geffen School of Medicine at UCLA Clinical Research Site, Los Angeles, California, United States

🇺🇸

4001, Lurie Children's Hospital of Chicago Clinical Research Site, Chicago, Illinois, United States

and more 47 locations

Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

First Posted Date
2014-04-17
Last Posted Date
2019-04-08
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
11
Registration Number
NCT02116660

Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB

Phase 3
Completed
Conditions
HIV/TB Co-infection
Interventions
Drug: Nevirapine
Drug: Efavirenz
First Posted Date
2013-03-06
Last Posted Date
2013-03-26
Lead Sponsor
All India Institute of Medical Sciences, New Delhi
Target Recruit Count
135
Registration Number
NCT01805258
Locations
🇮🇳

All India Institute of Medical Sciences, New Delhi, India

A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy

Phase 2
Completed
Conditions
HIV
Contraception
Interventions
Drug: Levonorgestrel
Drug: Nevirapine
Drug: Efavirenz
First Posted Date
2013-02-12
Last Posted Date
2023-09-01
Lead Sponsor
University of Nebraska
Target Recruit Count
60
Registration Number
NCT01789879
Locations
🇺🇬

Infectious Diseases Institute, Kampala, Uganda

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy